Swedbank AB Buys 28,882 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Swedbank AB boosted its stake in Jazz Pharmaceuticals by 2.7%, buying 28,882 shares to hold 1,102,974 shares (about 1.82%) valued at roughly $187.5 million.
• Jazz reported a strong Q1 beat with $6.34 GAAP EPS vs. a $4.67 consensus and revenue of $974.98 million (up ~19% YoY), though the company still shows a negative net margin and carries leverage (debt/equity ~1.0).
• Pipeline and market context: zanidatamab HER2+ 1L sBLA received Priority Review (PDUFA Aug. 25, 2026) as a potential high-value catalyst, analysts hold a consensus "Moderate Buy" with an average target of about $216.87, and insiders have sold ~74,015 shares (~$14.18M) in the last 90 days.

Swedbank AB boosted its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 2.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,102,974 shares of the specialty pharmaceutical company's stock after purchasing an additional 28,882 shares during the period. Swedbank AB owned about 1.82% of Jazz Pharmaceuticals worth $187,506,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of JAZZ. Dimensional Fund Advisors LP raised its holdings in Jazz Pharmaceuticals by 11.8% during the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock valued at $373,855,000 after buying an additional 298,815 shares during the last quarter. Ruffer LLP purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at about $2,425,000. Essex Investment Management Co. LLC bought a new position in shares of Jazz Pharmaceuticals during the third quarter valued at about $2,697,000. Sequoia Financial Advisors LLC purchased a new stake in shares of Jazz Pharmaceuticals during the third quarter worth about $605,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Jazz Pharmaceuticals by 8.5% in the third quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company's stock worth $246,092,000 after purchasing an additional 145,865 shares during the last quarter. Institutional investors own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $212.26 on Wednesday. The business's fifty day moving average is $190.45 and its 200 day moving average is $171.65. The company has a quick ratio of 1.67, a current ratio of 1.86 and a debt-to-equity ratio of 1.00. The stock has a market cap of $13.32 billion, a price-to-earnings ratio of -35.55, a PEG ratio of 0.36 and a beta of 0.27. Jazz Pharmaceuticals PLC has a twelve month low of $97.50 and a twelve month high of $212.57.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Tuesday, May 5th. The specialty pharmaceutical company reported $6.34 EPS for the quarter, beating the consensus estimate of $4.67 by $1.67. The business had revenue of $974.98 million during the quarter, compared to analyst estimates of $978.46 million. Jazz Pharmaceuticals had a positive return on equity of 6.87% and a negative net margin of 8.35%.The company's revenue for the quarter was up 19.1% on a year-over-year basis. During the same quarter last year, the firm posted $1.68 earnings per share. Research analysts expect that Jazz Pharmaceuticals PLC will post 20.51 EPS for the current fiscal year.

Jazz Pharmaceuticals News Summary

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Big EPS beat — Jazz reported $6.34 GAAP EPS vs. consensus $4.67, a sizable upside that materially exceeded expectations and is the main short-term catalyst for the stock. Article Title
• Positive Sentiment: Pipeline/regulatory boost — Zanidatamab HER2+ 1L global sBLA was granted Priority Review with a PDUFA date of Aug. 25, 2026, adding a potential high-value commercial catalyst. Article Title
• Positive Sentiment: Commercial execution — Management highlighted 19% YoY revenue growth and continued momentum in core drugs (Xywav up ~18% with net patient adds; Epidiolex up ~15%), supporting the beat and indicating durable demand. Article Title
• Neutral Sentiment: Guidance reaffirmed but ranges highlighted — Jazz reiterated 2026 revenue and expense guidance; public notes show a FY revenue range reported around $4.3B–$4.5B (consensus ~$4.5B), so guidance is stable but may be interpreted as slightly conservative by some investors. Article Title
• Neutral Sentiment: Mixed revenue read — Company reported strong YoY revenue growth (~19%), but some outlets noted the quarter was essentially flat vs. consensus (a small miss versus certain estimates). Investors will watch upcoming quarters for confirmation. Article Title
• Negative Sentiment: Profitability and balance-sheet considerations — Despite the EPS beat, Jazz still shows a negative net margin and carries leverage (debt-to-equity ~1.0), which could temper valuation upside for some investors. Article Title

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 55,600 shares of the business's stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $191.56, for a total transaction of $10,650,736.00. Following the sale, the executive vice president owned 56,862 shares of the company's stock, valued at $10,892,484.72. The trade was a 49.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Mary Elizabeth Henderson sold 5,343 shares of the company's stock in a transaction dated Thursday, February 26th. The stock was sold at an average price of $194.49, for a total transaction of $1,039,160.07. Following the completion of the sale, the senior vice president owned 28,728 shares in the company, valued at approximately $5,587,308.72. This trade represents a 15.68% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 74,015 shares of company stock worth $14,180,486 over the last 90 days. 4.30% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts have weighed in on JAZZ shares. Weiss Ratings reiterated a "sell (d+)" rating on shares of Jazz Pharmaceuticals in a report on Friday, March 27th. Wells Fargo & Company raised their price target on Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Morgan Stanley boosted their price objective on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the company an "overweight" rating in a research report on Wednesday, February 25th. Raymond James Financial initiated coverage on shares of Jazz Pharmaceuticals in a research report on Friday, April 10th. They issued an "outperform" rating and a $227.00 target price for the company. Finally, Bank of America lifted their target price on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the company a "buy" rating in a research note on Wednesday, February 25th. One analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $216.87.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.